ICON's cardiovascular trial experience, supported by a global team of experts
COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrityRead the whitepaper
In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US. Read how can medical device manufacturers sustain growth and successfully navigate this new model?Download the whitepaper
Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.Download the whitepaper
ICON experts share insights on ensuring patient safety and cardiovascular clinical trial integrity during the COVID-19 pandemic.
ICON recognises that the COVID-19 pandemic will have an impact on the conduct of ongoing and newly initiating clinical trials.
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19.
ICON experts discuss how the COVID-19 pandemic has led to the implementation of more efficient cardiovascular (CV) trial designs and operational execution.
The article discusses how, with the right approach and expert guidance, mHealth can help to collect new types of data and make trials more patient centric.
Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development.
Patients with cardiovascular disease are particularly susceptible to respiratory infections.